Hemab ApS: Financial statements 2025
CVR: 40837590
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Hemab ApS (CVR 40837590) has filed annual accounts for 2025. Equity in the 2025 report amounted to USD 196,000. The company had 54 employees in the financial year.
- Equity
- USD 196,000
- Employees
- 54
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | - | - | 196 t. USD | 54 |
| 2024 | - | - | - | 104 t. USD | 36 |
| 2023 | - | - | -22.8 mio. USD | 136.2 mio. USD | 21 |
| 2022 | - | - | -156.4 mio. | 6.1 mio. | 10 |
| 2021 | - | - | -35.2 mio. | 68 mio. | 3 |
Official annual report
How creditworthy is Hemab ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of October 23, 2025, Joseph Anderson has joined the board of directors of Hemab ApS.
As of October 23, 2025, Mårten Steen has left the board of directors of Hemab ApS.
Hemab ApS has published its annual report for 2024.
About Hemab ApS
Hemab ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab Hemophilia ApS. The management consists of Benny Sørensen and Mads Nikolaj Behrndt-Eriksen. The board consists of John Michael Maraganore (chair), Akshay Krishnadas Vaishnaw, Benny Sørensen and Linda Catharina Bain. The company is owned by Hemab Therapeutics Holdings, Inc.. According to the 2025 annual report, the company had an average of 54 employees. Equity in the 2025 report amounted to USD 196,000.